CD38 and cancer: As a result of these pleiotropic immune modulation, CD38 antibodies also enhance anti-tumor activity of others anti-cancer drugs with several studies highlighting that CD38-targeting antibodies have strong synergistic activity, such as combination to lenalidomide as well as to PD1/PD-L1 inhibitors (56, 68).